title: Update: peripheral T-cell lymphomas.
abstract: Peripheral T-cell lymphomas (PTCLs) are a group of biologically heterogeneous but typically aggressive diseases. Progress in understanding and developing optimal therapies for PTCLs has been hampered by disease rarity and only relatively recent recognition of the importance of the T-cell phenotype. The International Peripheral T-cell Lymphoma Project was a large collaborative effort to provide a broader understanding of prognosis. Recently, several new therapies have shown promise in the treatment of PTCLs.
authors.affiliation: British Columbia Cancer Agency, Vancouver, BC, Canada. ksavage@bccancer.bc.ca
authors.forename: Kerry J
authors.initials: KJ
authors.lastname: Savage
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D020869:Gene Expression Profiling; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000145:classification / Q000235:genetics / Q000628:therapy; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D033581:Stem Cell Transplantation; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone